Vimarsana
Biggest News Aggregation in the World

Neotorch Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neotorch Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neotorch Study Today - Breaking & Trending Today

Perioperative Toripalimab/Chemotherapy Combo Improves EFS in Resectable Stage III NSCLC - Vimarsana News

Perioperative Toripalimab/Chemotherapy Combo Improves EFS in Resectable Stage III NSCLC

Published: May 2, 2023

Perioperative toripalimab plus chemotherapy generated a median event-free survival benefit vs placebo plus chemotherapy in patients with resectable stage III non–small cell lung cancer.

Source: onclive.com
Related Topics:
Perioperative Toripalimab Plus Chemotherapy Patients With Resectable Stage Iii Non Small Cell Lung Cancer Neotorch StudyShun LuShanghai Jiaotong University
Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study - Vimarsana News

Junshi Biosciences Announces Toripalimab plus Chemotherapy Significantly Improved Event-free Survival (EFS) versus Chemotherapy as Perioperative Treatment for Resectable Stage III Non-small Cell Lung Cancer (NSCLC) in Phase 3 Neotorch Study

Published: April 20, 2023

Perioperative toripalimab plus chemotherapy significantly improved EFS and reduced risk of disease recurrence, progression events or death by 60% among resectable stage III NSCLC patients, compared to

Source: finanznachrichten.de
Related Topics:
United KingdomUnited StatesJunshi BiosciencesJunshi BioscienceZhi LiPr TeamNational Reimbursement Drug ListEuropean Medicines AgencyIr TeamDrug AdministrationShanghai Junshi Biosciences Co LtdRegulatory AgencyNeotorch StudySoutheast AsiaBiologics License ApplicationBreakthrough TherapyFast TrackOrphan DrugEmergency Use Authorizations